AUS
NZ
UK
CA
USA
IND
Global Health Limited, an ASX-listed healthcare technology company trading under ticker GLH, has informed the market of the lapse of 60,000 performance rights after their vesting conditions were not satisfied. These rights, identified by the security code GLHAB, expired on 11 May 2026 when the attached conditions were deemed unmet or impossible to fulfill. The company confirmed no payment was made in relation to this lapse. Post-expiry, Global Health holds 1,600,000 unquoted performance rights outstanding, while its total ordinary fully paid shares remain at 58,794,535.
Key Points
- Global Health Limited (ASX:GLH), a healthcare technology firm, filed an Appendix 3H on 15 July 2026.
- 60,000 unquoted GLHAB performance rights lapsed on 11 May 2026 due to unmet or unsatisfiable vesting conditions.
- No consideration was paid by the company regarding the cessation of these rights.
- Following the lapse, Global Health's capital structure includes 58,794,535 ordinary fully paid shares, 1,600,000 performance rights, 1,516,712 options, and 900,000 convertible notes.
- Investors should monitor for further lapses, new equity incentive grants, or capital structure updates in future disclosures.
Global Health Limited Reports Expiry of 60,000 GLHAB Performance Rights After Vesting Conditions Not Met
On 15 July 2026, Global Health Limited submitted an Appendix 3H notification to the ASX, disclosing that 60,000 performance rights under security code GLHAB ceased on 11 May 2026. The cessation resulted from the failure to meet or the impossibility of satisfying the conditions attached to these rights. This regulatory disclosure ensures transparency regarding changes in the company's issued capital.
Performance rights are commonly granted as long-term incentives to executives or key staff, contingent on achieving specific targets such as share price milestones, earnings goals, or service durations. When these conditions are unmet within the designated period, the rights expire without conversion to shares or compensation. Global Health confirmed no financial consideration was involved in this lapse.
Understanding the GLHAB Security Class Within Global Health’s Equity Structure
The GLHAB designation denotes a class of unquoted performance rights issued by Global Health Limited. Unlike ordinary shares traded on the ASX, these rights convert into shares only upon meeting defined vesting criteria and are thus excluded from quoted equity totals. Following the expiry of 60,000 GLHAB rights, 1,600,000 remain outstanding, representing active incentives that could dilute shareholders if converted.
Global Health’s Capital Composition After May 2026 Performance Rights Expiry
The company's Appendix 3H filing reveals that Global Health has 58,794,535 ordinary fully paid shares (GLH), forming the tradeable equity base. Additionally, the capital structure includes 1,516,712 options under GLHAI with varying expiry dates and exercise prices, 900,000 convertible notes under GLHAM, and the remaining 1,600,000 GLHAB performance rights. These unquoted instruments carry potential for future equity dilution depending on conversion conditions.
Reasons for Performance Rights Lapse and Implications for Stakeholders
Performance rights lapse when grant conditions—often set by the board and tied to financial or operational targets—are not fulfilled within the performance period. Global Health did not specify which conditions failed for the 60,000 GLHAB rights, as such detail is not mandatory in Appendix 3H filings.
For shareholders, the lapse generally reduces potential dilution, maintaining the ordinary share count at 58,794,535. However, the lapse may also reflect on the company’s performance against incentive benchmarks, which investors may consider when evaluating recent operational results.
Complexities Added by Convertible Notes and Options in Global Health’s Capital Structure
Besides performance rights, Global Health has 1,516,712 options (GLHAI) exercisable at various prices and expiry dates, and 900,000 convertible notes (GLHAM) that can convert into equity under certain terms. These instruments add layers to the company’s capital profile and influence dilution risk depending on market conditions and conversion terms. No updated terms were provided in this filing.
Regulatory Requirements for Appendix 3H Filings on Security Cessation
The Appendix 3H form is mandated by the ASX for any cessation of equity or debt securities through lapse, cancellation, conversion, or expiry. It requires disclosure of the security class, quantity, cessation reason, date, and any consideration paid, ensuring market transparency. Global Health’s filing on 15 July 2026 reported the 11 May 2026 lapse with no consideration paid. ASX cautions that capital figures may not reflect ongoing filings, a standard note applicable to all such disclosures.
Global Health’s Healthcare Technology Operations and Incentive Strategy Context
Operating in healthcare technology, Global Health delivers digital solutions supporting clinical and administrative functions. Equity-based incentives like performance rights are typical in this sector to retain and motivate key personnel. Although the 60,000 rights lapse is small relative to total capital, it provides insight into the company’s long-term incentive management. Details on the unmet conditions or personnel changes were not disclosed but may be found in the company’s annual or remuneration reports.
Immediate Effects of the GLHAB Performance Rights Expiry on Shareholders
The expiry does not affect the ordinary share count, which remains at 58,794,535. Since the lapsed rights had not converted into shares, no new shares were issued or cancelled, slightly reducing potential dilution. The filing supports governance transparency by informing the market of material capital changes. Although the number lapsed is small, it contributes to a comprehensive view of the company’s equity structure.
Future Outlook for Global Health’s Performance Rights and Incentive Programs
With 1,600,000 GLHAB performance rights still outstanding, investors should watch for further lapses, new grants, and disclosures on vesting conditions. These are typically reported in annual remuneration reports or shareholder meeting notices. Upcoming reporting periods and additional Appendix 3H or Appendix 2A filings will provide updates on incentive arrangements and potential equity issuance. No forward guidance on incentives was provided in this update.
